ADVA
1.4.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the European Advanced Networking Test Center (EANTC) has validated the interoperability of its unique carrier-grade network operating system (NOS) with routers and network management systems from a wide range of vendors. ADVA’s Ensemble Activator successfully demonstrated interoperability in a series of tests showing how disaggregated packet devices can significantly enhance the scale and functionality of networks. The software-based NOS, which turns bare-metal switches into powerful packet network devices, proved fully compatible with third-party switching and routing devices while supporting segment routing and MPLS Layer 3 services. What’s more, it showed ease of integration into third-party management systems through open interfaces for telemetry streaming and SDN control. Conducted at the EANTC’s facility in Berlin, the tests highlight the value of openness and show how Ensemble Activator can complement legacy packet networks with disaggregated packet devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005039/en/
“Putting our Ensemble Activator through EANTC’s rigorous tests emphasizes the commitment to openness and interoperability that underpins all ADVA innovation. But we’re also showing the industry how we can bring something special to Layer 3. Our years of experience with lower layer solutions give us a unique understanding of the operational aspects of networks,” said Eli Angel, VP, product line management, ADVA. “Our Ensemble Activator is proven to enable high-value disaggregated cell site gateway solutions, bringing the agility of software-based feature development to mobile networks. Now, we’re going even further and extending our unique MEF 3.0-certified solution with higher layer networking capabilities. These tests highlight how our Ensemble Activator supports segment routing and MPLS. What more, our disaggregated packet solution releases communication service providers from vendor lock-in and delivers total agility.”
Engineered specifically for white box switching, ADVA’s Ensemble Activator is the result of years of experience in deploying optical, Carrier Ethernet and IP/MPLS networks. The NOS is designed for zero-touch provisioning using the Open Networking Install Environment (ONIE) framework. Its success in the latest round of EANTC tests demonstrates how Ensemble Activator’s open management and control interfaces support easy integration into multi-vendor networks. ADVA’s strategy of extending its software capabilities from Layer 2 to higher layer functions offers the market a fresh approach to deploying flexible, feature-rich software-based MPLS routing and segment routing solutions in an open environment. ADVA’s long experience of building disaggregated telecommunication infrastructure will bring a host of benefits to operators and users of virtual private networks.
“Our evaluation confirms that Ensemble Activator successfully interworked with third-party routers and network management systems. In environments featuring technology from other major vendors, ADVA’s disaggregated software NOS was verified in tests focused on Layer 2 and Layer 3 VPNs, segment routing, and control and data plane capabilities,” commented Carsten Rossenhövel, managing director, EANTC. “This latest interoperability event was a major success with more than 100 attendees from 16 vendors, including many participating remotely. Its program reflected a shift across the industry to software-defined networking with many testing scenarios involving programmability and manageability. ADVA’s Ensemble Activator easily integrated and successfully interoperated in several of these tests, such as those focused on vendor-neutral Layer 3 segment routing and telemetry streaming.”
Further information on the interoperability testing is available on the EANTC website: https://adva.li/eantc-2020 .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About EANTC
EANTC (European Advanced Networking Test Center) is internationally recognized as one of the world's leading independent test centers for telecommunication technologies. Based in Berlin, Germany, the company offers vendor-neutral consultancy and realistic, reproducible high-quality testing services since 1991. Customers include leading network equipment manufacturers, tier-1 service providers, large enterprises and governments worldwide. EANTC's proof of concept, acceptance tests and network audits cover established and next-generation fixed and mobile network technologies. www.eantc.de
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005039/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom